# Antimicrobial Resistant Gram-Negative Infections

**Guideline Reference:** [IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections](https://www.idsociety.org/practice-guideline/amr-guidance/#Extended-Spectrum%CE%B2-Lactamase-ProducingEnterobacterales) (July 18, 2023)

**Guideline Scope:** This guideline focuses on ESBL Enterobacterales, AmpC ESBL, CPE, MDR Pseudomonas, Carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia.

# ESBL-E
ESBLs are enzymes that inactivate most penicillins, cephalosporins, and aztreonam. EBSL-E generally remain susceptible to carbapenems. ESBLs do not inactivate non–β-lactam agents (eg, ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin). However, organisms carrying ESBL genes often harbor additional genes or mutations in genes that mediate resistance to a broad range of antibiotics.

ESBL-Enterobacterales is growing in community prevalence in the USA. Any gram-negative organism has the potential to harbor ESBL genes; however, they are most prevalent in _Escherichia coli_, _Klebsiella pneumoniae_, _Klebsiella oxytoca_, and _Proteus mirabilis_.

| Infection                          | Recommended Regimen                                                                                                                                                                                                                                                                                                          |
| ---------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Uncomplicated Cystitis             | **Nitrofurantoin, TMPSMX.** Less preferred are cipro, levoflox, and carbapenems. Single dose aminoglycosides and oral fosfomycin are also alternatives.                                                                                                                                                                      |
| Pyelonephritis and complicated UTI | **TMP-SMX, ciprofloxacin, or levofloxacin** are preferred treatment options. Ertapenem, meropenem, imipenem are second-line. Aminoglycosides for a full treatment course are an alternative. Fosfomycin and nitrofurantoin do not achieve adequate concentrations in the renal parenchyma and are therefore not recommended. |
|                                    |                                                                                                                                                                                                                                                                                                                              |





# Antibiotic Dosing

[![](https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/1.0/table-1.png)](https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/1.0/idsa-amr-guidance-v3.0.pdf#page=6)